A specific subset includes myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase (TK) gene fusions, particularly involving <i>PDGFR A</i> or <i>B</i>, which are sensitive to TK inhibitor treatment. The gene discussed is TKT; the disease is Increased total eosinophil count.